¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary amine"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • secondary shock
    ÀÌÂ÷¼îÅ©, ¼Ó¹ß¼îÅ©
  • secondary sterility
    ¼Ó¹ßºÒÀÓ
  • secondary suture
    ÀÌÂ÷ºÀÇÕ
  • secondary tuberculosis
    ¼Ó¹ß°áÇÙ
  • secondary wound closure
    ÀÌÂ÷»óóºÀÇÕ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • secondary adaptation
    Á¦ÀÌÂ÷¼øÀÀ(Ì¡Ëö̤ËàËô).
  • secondary adhesion
    2Â÷¼º À¯Âø(¡­À¯Âø).
  • secondary adhesion
    ÀÌÂ÷¼º À¯Âø(¡­àõë¨ó·)
  • secondary aldosteronism
    ¼Ó¹ß¼º ¾Ëµµ½ºÅ× ·ÐÁõ.
  • secondary aldosteronism
    ¼Ó¹ß¼º ¾Ëµµ½ºÅ× ·ÐÁõ(¡­ñø)
  • secondary amenorrhea
    2Â÷¼º(¼Ó¹ß¼º)¹«¿ù°æ(áÙÛ¡àõÙíêÅÌè).
  • secondary amenorrhea
    ¼Ó¹ß¼º ¹«¿ù°æ(áÙÛ¡àõÙíêÅÌè)
  • secondary amputation
    2Â÷Àý´Ü(¡­Ã¼´Ü).
  • secondary amputation
    ÀÌÂ÷Àý´Ü(¡­ôîÓ¨)
  • secondary amyloidosis
    ÀÌÂ÷¼º ¾Æ¹Ð·ÎÀÌ µåÁõ.
  • secondary anal opening
    2Â÷Ç×¹®±¸ (¡­Ç×¹®±¸).
  • secondary anal opening
    ÀÌÂ÷Ç×¹®±¸ (¡­ùýڦϢ)
  • secondary anemia
    ¼Ó¹ß¼º ºóÇ÷(áÙÛ¡àõ Þ¸úì).
  • secondary anemia
    ¼Ó¹ß¼º ºóÇ÷(áÙÛ¡àõ Þ¸úì)
  • secondary aneurysm
    2Â÷¼º µ¿¸Æ·ù(ÀÌÂ÷¼ºµ¿¸Æ·ù).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Haploid secondary gametocyte
    Ȭ¹è¼öüÀÌÂ÷»ý½Ä¼¼Æ÷
    [¿¾ ¿ë¾î] ¹Ý¼öüÁ¦ÀÌ»ý½Ä¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • super-secondary structure
    ÃÊÀÌÂ÷ ±¸Á¶(õ±ì£ó­Ï°ðã)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
VAT variable antigen type; ventricular accommodation test; ventricular activation time; vesicular amine ...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
CPSC congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission
HSH hypomagnesemia with secondary hypocalcemia
HSRD hypertension secondary to renal disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SMC secondary mesenchyme cell
SP-MS secondary progressive MS
HM-PAO hexamethyl propylene amine oxyme
99TCm-HMPAO 99TCm-hexamethylpropylene amine oxime
HMPAO 99Tc]hexamethylpropylene amine oxime
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • secondary inoculation
    ÀÌÂ÷ Á¢Á¾
  • secondary lesion
    ÀÌÂ÷¼º º´º¯, ÀÌÂ÷ ¹ßÁø, ¼Ó¹ßÁø
  • secondary local muscle soreness
    ¼Ó¹ß¼º ±¹¼Ò ±Ùµ¿Åë
  • secondary occlusal trauma
    ¼Ó¹ß¼º ±³ÇÕ ¿Ü»ó
    ÀÌ¹Ì Ä¡ÁÖ ÁúȯÀÌ ÀÖ´Â Ä¡¾Æ¿¡ °¡ÇØÁø °úµµÇÑ ±³ÇÕ·ÂÀ¸·Î ÀÎÇÑ Ä¡ÁÖ Á¶Á÷ÀÇ ¿Ü»ó.
  • secondary ossification center
    ÀÌÂ÷ °ñÈ­ Áß½É
  • secondary osteon
    ÀÌÂ÷ »À ´ÜÀ§
  • secondary pain
    ¼Ó¹ß¼º ÅëÁõ, Á¦ÀÌ µ¿Åë
    µ¿ÀǾî=referred
  • secondary palate
    ÀÌÂ÷ ±¸°³
  • secondary pathway
    ÀÌÂ÷ °æ·Î
  • secondary pneumonia
    ¼Ó¹ß¼º Æó·Å
  • secondary sex characteristic
    ÀÌÂ÷ ¼ºÂ¡
  • secondary source
    ÀÌÂ÷ ¿äÀÎ
  • secondary sterility
    ¼Ó¹ß ºÒÀÓ
  • secondary structure
    ÀÌÂ÷ ±¸Á¶
  • secondary syphilis
    ÀÌÂ÷ ¸Åµ¶, 2±â ¸Åµ¶
    s
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
secondary alcohol An alcohol characterised by the bivalent atom group
(05 Mar 2000)
secondary aldosteronism Aldosteronism resulting not from a defect intrinsic to the adrenal cortex but from a stimulation of hormonal secretion caused by extra-adrenal disorders; associated with increased plasma renin activity and occurs in heart failure, nephrotic syndrome, cirrhosis, and hypoproteinaemia.
(05 Mar 2000)
secondary amenorrhoea Amenorrhoea in which the menses appeared at puberty but subsequently ceased.
(05 Mar 2000)
secondary amputation Amputation performed some time after a previous amputation that has failed to heal satisfactorily.
(05 Mar 2000)
secondary amyloidosis Amyloidosis occurring in association with another chronic inflammatory disease; organs chiefly involved are the liver, spleen, and kidneys, and the adrenal glands less frequently.
(05 Mar 2000)
secondary anaesthetic A compound that contributes to, but is not primarily responsible for, loss of sensation when two or more anaesthetics are simultaneously administered.
(05 Mar 2000)
secondary antibody deficiency Immunodeficiency in which there is no evident defect in the lymphoid tissues, but rather hypercatabolism or loss of immunoglobulins such as occurs in familial idiopathic hypercatabolic hypoproteinaemia or in defects associated with the nephrotic syndrome.
Synonym: secondary agammaglobulinaemia, secondary antibody deficiency, secondary hypogammaglobulinaemia.
(05 Mar 2000)
secondary antibody response An antibody made upon second (subsequent) exposure to an antigen, mostly of the class IgG.
(09 Oct 1997)
secondary aortic area Region of the chest at the mid-left sternal bases where aortic diastolic murmurs are often best heard.
(05 Mar 2000)
secondary atelectasis A nonexpansion of the lungs after birth is known as primary atelectasis. Secondary atelectasis can occur at any age but is common in infants due to hyaline membrane disease. This form may also be seen in patients after surgery (general anaesthesia).
See: atelectasis.
(27 Sep 1997)
secondary axis Any ray passing through the optical centre of a lens.
(05 Mar 2000)
secondary buffer See: Hamburger's law.
(05 Mar 2000)
secondary calcium phosphate CaHPO4-2H2O;used as a calcium and phosphorus dietary supplement.
Synonym: calcium monohydrogen phosphate, secondary calcium phosphate.
(05 Mar 2000)
secondary carcinoma <tumour> A carcinoma that has appeared in a region remote from its site of origin, as in metastasis.
Synonym: secondary carcinoma.
(05 Mar 2000)
secondary cardiomyopathy Disease that affects the myocardium secondarily to systemic disease, infection, or metabolic disease.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á